88results about "Depsipeptide ingredients" patented technology

The invention provides application of a deacetylase inhibitor or a derivative thereof and application of a pharmaceutical composition, and belongs to the technical field of biology. The application of the deacetylase inhibitor or the pharmaceutically acceptable derivative thereof comprises the application of the deacetylase inhibitor for preparing a medicine for treating osteoporosis; wherein the deacetylase inhibitor is used for inducing histone acetylation in a cell nucleus. By inducing acetylation of histone in a cell nucleus, the differentiation direction of the bone marrow mesenchymal stem cells is accurately and efficiently controlled, and a treatment scheme for osteoporosis related diseases is developed.

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and / or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and / or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and / or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and / or cancers; and methods for inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

Embodiments of the present invention relate to a novel compound of Formula (I)or stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in treatment of infection caused by Gram-negative bacteria.

The present invention relates to a composition comprising tigolaner and, optionally endoparasiticidal agents, a method for its manufacture and its use as a medicament for controlling parasites. Compositions can include tigolaner and 1,2-isopropylideneglycerol, or the composition can include praziquantel, emodepside a solvent component, and tigolaner. The composition can be used in the treatment and / or prevention of parasite infections in animals.

The present invention relates to a composition comprising tigolaner and, optionally endoparasiticidal agents, a method for its manufacture and its use as a medicament for controlling parasites. Compositions can include tigolaner and 1,2-isopropylideneglycerol, or the composition can include praziquantel, emodepside a solvent component, and tigolaner. The composition can be used in the treatment and / or prevention of parasite infections in animals.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic. In certain instances the immunotherapeutic is a chimeric antigen receptor T cell, an antibody or polypeptide that binds a checkpoint inhibitor, or a vaccine.

Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Disclosed herein, are methods for treating, preventing or inhibiting a coronavirus infection or a disease or condition associated with a coronavirus infection. The methods can comprise administering to the subject one or more therapeutically effective doses of valproic acid and docosahexaenoic acid.

Embodiments of the disclosure include methods and compositions for treatment of cancer, autoimmune disorders, and / or infectious disease. In particular embodiments, antigen expression on target cells is increased with epigenetic modulators in conjunction with immune effector cells engineered to express a heterologous molecule that targets the target cells. In specific embodiments, the epigenetic modulators are used in conjunction with NK cells expressing a chimeric antigen receptor that targets a cancer antigen, an antigen associated with an autoimmune disorder, or an antigen associated with a pathogen.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

This method for producing a co-crystal containing a cyclic peptide and a compound having a melting point of 20 DEG C or higher comprises a step of bringing the cyclic peptide into contact with the compound and a solvent.

The present invention provides pharmaceutical compositions of teixobactin that are capable of preventing gelation of teixobactin. The pharmaceutical compositions comprise teixobactin and a pegylated phospholipid. The present invention also provides methods of preparing the pharmaceutical compositions of teixobactin and methods of treating a subject using the pharmaceutical compositions of teixobactin.

The present disclosure describes a novel method for decellularizing amphibian extracellular matrix to obtain isolated ECM that is substantially free of cellular and nuclear debris. The method includes washing the amphibian ECM in a solution containing one or more detergents, incubating the ECM with one or more proteases, and incubating the ECM with one or more nucleases. The present disclosure also describes various methods of using the isolated ECM.

Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.

The present invention relates to the use of compounds in the treatment of autoimmune conditions, in particular in the treatment of rheumatoid arthritis.

The present invention provides a use of beauvericin in manufacturing a medicament for inhibiting angiogenesis, in which the therapeutically effective concentration of beauvericin ranges from 0.1 µM to 5 µM; which can be used for preparation of a medicament for preventing or treating a retinal disorder, or a pharmaceutical composition or combination with an anti-cancer drug for treating a cancer.

The present disclosure describes a novel method for decellularizing amphibian extracellular matrix to obtain an isolated ECM that is substantially free of cellular and nuclear debris. The method includes washing the amphibian ECM in solutions containing one or more surfactants, incubating the ECM with one or more proteases, and incubating the ECM with one or more nucleases. The present disclosure also describes various methods of using the isolated ECM.

The application belongs to the field of natural medicines, and particularly relates to cyclic peptide natural products-xylonic acid peptides and the use thereof in the preparation of anti-parasitic drugs. Specifically, 12 cyclic peptide natural products containing xylonic acid structural units are disclosed, which exhibit different degrees of anti-parasitic activity in biological activity tests and have wide application value.

This medicament characterized by containing, together or separately in combination with a HDAC inhibitor, an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein is useful as a medicament for treatment and / or prevention of cancer.

To provide a composition for inhibiting fibrosis in ocular tissue.SOLUTION: A drug composition comprises a substance that inhibits fibrosis in a plurality of ocular tissues.SELECTED DRAWING: None

The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss by modulating the rate of Atoh1 protein degradation to increase levels of Atoh1 protein.

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and / or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and / or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and / or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and / or cancers; and methods for inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HIDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

The present invention provides a process and intermediates for producing GIP / GLP1 dual agonist peptides, tilzepatide, or pharmaceutically acceptable salts thereof. [Solution] A process is provided for converting a depsipeptide isomer into a desired peptide, comprising: a. adjusting the pH of the depsipeptide isomer to approximately pH 7 to approximately pH 10; and b. incubating the depsipeptide isomer at pH 7 to pH 10 for at least 1 hour.

Provided herein are multifunctional molecules comprising T cell receptor variable beta-binding moieties and cytokines and methods of treating conditions or diseases in a subject using the same. Also provided herein is a combination therapy using the multifunctional molecules comprising T cell receptor variable beta-binding moieties and cytokines and an HDAC inhibitor.

A PI3K delta inhibitor or a pharmaceutically acceptable salt thereof for use in treating a hematological malignancy in a subject, the treatment comprising administering to the subject i) the PI3K delta inhibitor or a pharmaceutically acceptable salt thereof, and ii) an HDAC inhibitor or a pharmaceutically acceptable salt thereof, separately, sequentially, or simultaneously. The treatment can also further comprise administering to the subject iii) a further chemotherapeutic agent, separately, sequentially, or simultaneously.